

RSC Advances




This is an *Accepted Manuscript*, which has been through the Royal Society of Chemistry peer review process and has been accepted for publication.

Accepted Manuscripts are published online shortly after acceptance, before technical editing, formatting and proof reading. Using this free service, authors can make their results available to the community, in citable form, before we publish the edited article. This *Accepted Manuscript* will be replaced by the edited, formatted and paginated article as soon as this is available.

You can find more information about *Accepted Manuscripts* in the [Information for Authors](#).

Please note that technical editing may introduce minor changes to the text and/or graphics, which may alter content. The journal's standard [Terms & Conditions](#) and the [Ethical guidelines](#) still apply. In no event shall the Royal Society of Chemistry be held responsible for any errors or omissions in this *Accepted Manuscript* or any consequences arising from the use of any information it contains.

Table of contents entry



A novel reduction-sensitive pullulan-based biocompatible material can self-assemble into nanomicelles and release loaded drug triggered by reductive condition.

Novel reduction-sensitive pullulan-based micelles with good hemocompatibility for efficient intracellular doxorubicin delivery

Xianwu Wang,^a Jingyun Wang,^{*ab} Yongming Bao,^a Benhua Wang,^b Xiaohong Wang,^a Lili Chen^a

5

^a *School of Life Science and Biotechnology, Dalian University of Technology, Dalian 116024, PR China*

^b *State Key Laboratory of Fine Chemicals, Dalian University of Technology, Dalian 116024, PR China*

10

* Corresponding author at: School of Life Science and Biotechnology, Dalian University of Technology, No. 2 Linggong Road, Ganjingzi District, Dalian 116024, PR China. Tel.: +86 411 84706355; fax: +86 411 84706365.

E-mail address: wangjingyun67@dlut.edu.cn (J. Wang).

20

Abstract

A novel intracellular reduction-sensitive delivery system of doxorubicin (DOX), based on pullulan-stearic acid (P-ss-SA) conjugates with disulfide bonds as reduction-sensitive bond, was successfully developed. The conjugates could self-assemble into micelles in aqueous media and encapsulate DOX. The properties of blank and DOX-loaded micelles were studied in detail. The results showed that the mean size of the blank and DOX-loaded micelles was around 187.7 nm and 194.4 nm, respectively. The drug loading content and encapsulation efficiency of the P-ss-SA micelles were around 6.19% and 65.53%, respectively. The mean size of reduction-sensitive P-ss-SA micelles increased dramatically under reductive conditions. The drug release of P-ss-SA micelles under reductive conditions was much faster than that under non-reductive conditions. The confocal laser microscopy and flow cytometry measurements indicated that the intracellular reductive conditions broke the disulfide bonds in P-ss-SA micelles and triggered the fast release of DOX. The in vitro IC_{50} of the DOX-loaded P-ss-SA micelles was lower than that of DOX-loaded micelles without reduction-sensitivity against HepG2 and MCF-7 cells. The blank micelles showed negligible cytotoxicity, possessed excellent hemocompatibility without causing undesirable hemolysis. These results indicated that the biocompatible reduction-sensitive P-ss-SA micelles can be used as potential carrier systems for the intracellular delivery of DOX.

Keywords: Reduction-sensitive, Pullulan, Micelle, Hemocompatibility, Doxorubicin

45 1. Introduction


Biodegradable polymeric micelles have emerged as one of the most promising nanocarrier systems for anticancer drug delivery.¹⁻⁶ These biodegradable polymeric micelles can improve the bioavailability of anticancer drugs and reduce the side effects of the drugs by increasing the solubility and stability of anticancer drugs, prolonging drug blood circulation
50 time and improving drug accumulation at tumor tissue via the enhanced permeability and retention (EPR) effect.⁷⁻⁹ These polymeric micelles could disassemble rapidly and give burst drug release intracellularly because of stimuli such as pH,¹⁰⁻¹⁴ temperature,¹⁵ ultrasound,¹⁶ enzyme,¹⁷ light,¹⁸ redox potential.¹⁹ Among these biodegradable polymeric micelles, reduction-sensitive polymeric micelles containing disulfide bonds in the main chain, at the
55 side chain, or in the cross-linker have been intensively studied for enhanced intracellular drug release due to the great difference in the redox potential between the mildly oxidizing extracellular milieu and the reducing intracellular milieu.²⁰⁻²² The significant difference in the redox potential mainly contributes to the concentration of glutathione (GSH), a thiol-containing tripeptide capable of reducing disulfide bonds, which is mM concentrations in
60 the cell cytoplasm and even higher level in cancer cells, while only μM concentrations in blood plasma due to rapid enzymatic degradation.^{23, 24} Based on this, a lot of reduction-responsive polymeric micelles have been designed and used as anticancer drug carrier.^{7, 8, 25-30}

Pullulan (P), a water-soluble and neutral linear polysaccharide produced by
65 *Aureobasidium pullulans*, is formed from α -1,4-linked glucose units included in a α -1,6-linked maltotriose unit.³¹ P has been widely explored recently for its biomedical applications in tissue

engineering, targeted drug and gene delivery due to its good biological nature such as nontoxic, non-immunogenic, non-mutagenic and non-carcinogenic nature.³²⁻³⁵ In addition, P has been verified that it can specifically interact with asialoglycoprotein receptor (ASGPR) present on liver parenchymal hepatocytes and it is an ideal material to prepare active liver-targeting carriers.^{12, 35-38} Although there have been many P-based amphiphilic copolymers for drug delivery, to the best of our knowledge, few studies have focused on redox-sensitive P-based amphiphilic copolymers for doxorubicin (DOX) delivery.³⁹

In our previous report, we synthesized stearic acid (SA) modified P derivatives with different degrees of substitution.⁴⁰ The stearic acid modified P derivatives (PUSAs) can self-assembled in water and efficiently encapsulate DOX. But the DOX-loaded micelles exhibited gradual drug release over a long time and a reduced antitumor efficacy against MCF-7 cells. In this study, we for the first time introduced stearic acid (SA) into P using cystamine as bioreducible linkages to form redox-sensitive micelles (P-ss-SA) for triggered intracellular doxorubicin release (Scheme 1). Insensitive P-SA conjugates which were structurally analogous to P-ss-SA were also synthesized for comparison. The physicochemical characteristics and DOX-loading capacities of micelles were investigated by dynamic light scattering (DLS), transmission electron microscopy (TEM), and fluorescence spectroscopy. The effective disulfide bond breakage of the micelles and triggered DOX release in response to dithiothreitol (DTT) medium imitating reduction condition in human body were demonstrated by the observations of size change and in vitro DOX release study. The cytotoxicity of blank and DOX-loaded micelles was studied in HepG2 cells and MCF-7 cells by the MTT assay. The blood compatibility of blank micelles was also evaluated by hemolysis

test. The behavior of the intracellular release of DOX was further studied in MCF-7 cells by
 90 confocal laser scanning microscopy (CLSM) and flow cytometry (FCM).



Scheme 1. The illustration of drug release from reduction-sensitive P-ss-SA micelles.

2. Materials and methods

2.1. Materials

95 Pullulan (P, MW: 100 kDa) was purchased from Shandong Zhongqing Biotechnology Company. 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride (EDC), N-hydroxysuccinimide(NHS), 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), trypsin, 4-dimethylaminopyridine (DMAP), pyrene, cystamine dihydrochloride, adipic acid dihydrazide, dithiothreitol (DTT), triethylamine (TEA) and other chemicals were
 100 all obtained from Sigma-Aldrich (St. Louis,USA). Doxorubicin hydrochloride (DOX·HCl) was purchased from Dalian Meilun Biotechnology Co., Ltd., China.

Human hepatocellular liver carcinoma cell (HepG2) and human breast cancer cell (MCF-7) were purchased from the Institute of Biochemistry and Cell Biology, SIBS, CAS.

Dulbecco's modified Eagle's medium (DMEM) and fetal bovine serum (FBS) for cell culture
105 were obtained from Hyclone (Logan, USA).

2.2. Synthesis of P-ss-SA conjugates and P-SA conjugates

2.2.1. Synthesis of pullulan succinate (P-COOH)

P-COOH was prepared as previously described³¹ with some modifications. Briefly, P
(1.62 g, 10 mM) was dissolved in 30 mL dimethyl sulfoxide (DMSO) and then added with
110 succinic anhydride (0.8 g, 8 mM) and DMAP (0.2 g, 1.64×10^{-3} mol). The mixture was stirred
at 50 °C for 24 h under nitrogen. After the reaction was completed, the reaction mixture was
poured into 500 mL of absolute ethyl alcohol to precipitate P-COOH. The P-COOH obtained
by centrifugation was redissolved in 10 mL of deionized water and dialyzed (MWCO 10000)
against deionized water for 72 h. The P-COOH solution was lyophilized and stored at 4 °C
115 until further use.

2.2.2. Synthesis of cystamine modified pullulan succinate (P-CYS) and adipic dihydrazide modified pullulan succinate (P-ADH)

P-CYS was prepared by the modification of P-COOH with cystamine. First, P-COOH
(1.42 g, $n_{\text{-COOH}} = 3.25$ mM) was dissolved in 100 mL PBS (0.2 M, pH 7.8) and then added
120 with EDC (631.9 mg, 3.25 mM) and NHS (381.3 mg, 3.25 mM). The mixture was stirred at 4
°C for 4 h to activate the carboxyl groups of P-COOH. Then, cystamine dihydrochloride (3.73
g, 16.25 mM) was added and the reaction mixture was stirred at 30 °C for 24 h. The resulting
solution was dialyzed (MWCO 10000) exhaustively against 0.1 M NaCl and then deionized
water to remove unreacted cystamine, EDC and NHS coupling agents. Finally, the polymer
125 P-CYS solution was lyophilized and stored at 4 °C until further use.

Adipic dihydrazide modified pullulan succinate (P-ADH) was carried out according to the following procedures. First, P-COOH (1.51 g, $n_{\text{-COOH}} = 3.46$ mM) was dissolved in 150 mL PBS (0.2 M) and adipic dihydrazide (3.08 g, 17.3 mM) was added with agitation. The pH of the reaction mixture was adjusted to 4.75, followed by addition of EDC (672.7 mg, 3.46 mM). The reaction was carried out at 30 °C for 12 h. The pH of resulting solution was adjusted to 7.0 by addition of 0.1 M NaOH. Then the solution was dialyzed (MWCO 10000) exhaustively against 0.1 M NaCl, 25% EtOH/H₂O, deionized water, each for 3 days with six exchanges. Finally, the polymer P-ADH solution was lyophilized and stored at 4 °C until further use.

135 2.2.3. Synthesis of amphiphilic P-ss-SA conjugates and P-SA conjugates

Amphiphilic P-ss-SA conjugates and P-SA conjugates were prepared by chemical grafting stearic acid (SA) to P-CYS and P-ADH, respectively. In brief, carboxyl group of SA was reactivated by equimolar amounts of EDC and NHS in DMSO at 30 °C for 1 h., then the SA solution containing EDC and NHS was added dropwise to P-CYS (110 mg, $n_{\text{-NH}_2} = 0.23$ mM) or P-ADH (110 mg, $n_{\text{-NH}_2} = 0.23$ mM) dissolved in 30 mL of DMSO under vigorous stirring, in which the molar ratio of SA to free amines in P-CYS or P-ADH was 0.063. The reaction was continued at 30 °C for 72 h to ensure high conversion. The resulting solution was poured into excess amount of absolute ethyl alcohol to precipitate P-ss-SA or P-SA. After being centrifuged, the precipitation was redissolved in 10 mL of deionized water and dialyzed (MWCO 10000) against deionized water for 72 h. Finally, the polymer P-s-s-SA and P-SA solutions were lyophilized and stored at 4 °C until further use.

145 2.3. Characterization of P-ss-SA conjugates and P-SA conjugates

¹H NMR spectra of P-COOH, P-CYS, P-ADH, P-ss-SA conjugates and P-SA conjugates were acquired in D₂O using a 400 MHz spectrometer (Varian INOVA400, USA). The degree of succinoylation of P-COOH was quantified by titration against a standard NaOH solution with phenolphthalein as an indicator. The degree of substitution (DS) of P-CYS or P-ADH which is defined as the number of free amines per 100 glucose residues of P was estimated using elemental analysis.

2.4. Preparation and characterization of micelles

2.4.1. Preparation of P-ss-SA micelles and P-SA micelles

The reduction-sensitive P-ss-SA micelles were prepared by dialysis method. Briefly, 10 mg of P-ss-SA conjugates were dissolved in 3 mL DMSO. To form nanoparticles, the solution was injected in dialysis bag (MWCO 10000) and dialyzed against 1000 ml deionized water for 48 h with six exchanges followed by sonication using a probe-type ultrasonicator (UP 200H, dr. hielscher, GmbH) at 50 W for 60 s. The resulting micellar solution was filtered through a 0.45 μm pore-sized microporous membrane and then stored at 4 °C. Non-reduction-sensitive P-SA micelles were prepared with the same protocol by using P-SA conjugates.

2.4.2. Characterization of P-ss-SA micelles and P-SA micelles

The particle size and zeta potential were measured by dynamic light scattering (DLS) using a Malvern Zetasizer Nano-ZS90 (Malvern instruments, UK). All of the DLS measurements were performed at 25 °C and at a scattering angle 90°. The concentration of micelles was kept constant at 0.5 mg/mL in deionized water. All samples were tested in triplicate.

170 The morphology of micelles was observed by transmission electron microscopy (TEM, Tecnai G2 Spirit 120 kV). The samples were prepared by dropping 0.5 mg/mL micellar solution on the copper grid, followed by air drying and negatively stained with 2% (w/w) uranyl acetate for 2 min. The grid was dried at room temperature and then observed by TEM.

The critical micelles concentration (CMC) of amphiphilic P-ss-SA conjugates and P-SA
175 conjugates was evaluated by fluorescence spectroscopy (LS55, PerkinElmer), using pyrene as the probe. To prepare sample solutions, a known amount of pyrene in methanol was added to each 10 mL test tubes and then methanol was evaporated. 10 mL of different concentrations of micellar solutions was added to give a final pyrene concentration of 6.0×10^{-7} M. The samples were sonicated for 40 min in an ultrasonic bath and shaken in a shaking air bath at 37 °C for 1
180 h. The fluorescence excitation spectra were measured at an emission wavelength of 334 nm, and the emission spectra was recorded in the range of 350-450 nm. The excitation and emission bandwidths were 5 and 2.5 nm, respectively.

2.5. Disassembly of micelles triggered by DTT

The disassemble behaviors of reduction-sensitive P-ss-SA micelles in response to 10 mM
185 DTT (PBS; 10 mM, pH 7.4) imitating the intracellular reductive condition was monitored by DLS measurement and P-ss-SA micelles without the addition of DTT as a control. The disassembly of P-SA micelles in response to 10 mM DTT was also measured for comparison. Briefly, to a glass cell containing 3 mL solution of P-ss-SA micelles or P-SA micelles (0.5 mg/mL), was added 10 mM DTT at predetermined time. The solution was placed in a shaking
190 bed at 37 °C at a rotation speed of 180 rpm. The micelle size was measured by DLS through 24 h.

2.6. Preparation and characterization of DOX-loaded micelles

DOX-loaded micelles were prepared by a simple dialysis method.²⁵ Before loading DOX into the micelles, DOX·HCl was stirred overnight with twice the number of moles of TEA to obtain the DOX base. Then the DOX/DMSO solution was added into the DMSO solution of P-ss-SA conjugates or P-SA conjugates. The mixture was placed in a shaking bed at 37 °C at a rotation speed of 180 rpm for 3 h to get well mixed. The final mixture was dialyzed (MWCO 10000) against deionized water for 48 h. Afterwards, The solution was filtered through a 0.45 μm pore-sized microporous membrane and then lyophilized.

The entrapment efficiency (EE) and drug-loading (DL) were obtained on the basis of the standard curve by using the UV/VIS Spectrophotometer (JASCO V-560). Lyophilized DOX-loaded polymeric micelles were dissolved in a mixture of DMSO/H₂O (v/v, 9/1) to obtain clear solution, and the drug concentration was quantified by its absorbance at 485 nm. The EE and DL were calculated by the formulas as $EE(\%) = (\text{weight of DOX in micelles}) / (\text{weight of DOX fed initially}) \times 100\%$ and $DL(\%) = (\text{weight of DOX in micelles}) / (\text{weight of polymeric micelles containing DOX}) \times 100\%$, respectively.

2.7. In vitro drug release from micelles triggered by DTT

The release profiles of DOX from P-ss-SA micelles and P-SA micelles were studied using a dialysis method. Lyophilized DOX-loaded P-ss-SA micelles or P-SA micelles containing 0.2 mg DOX were suspended in 2 mL of PBS (10 mM, pH 7.4) and placed in a dialysis tube (MWCO 10000). Then the tube was immersed in release media (100 mL PBS; 10 mM, pH 7.4) with or without 10 mM DTT in a shaking water bath at 37 °C. At predetermined time intervals, 3 mL of release media was withdrawn and replaced with 3 mL of the

corresponding fresh buffer solution. The amount of DOX release was determined by
215 fluorescence measurement (excitation at 485 nm).

2.8. Hemolysis test

1 mL sheep blood sample was added to 2 mL PBS, and then red blood cells (RBCs) were
isolated from serum by centrifugation at 2000 rpm for 5 min. The supernatant containing
plasma and platelets was discarded. The washing procedure was continued with PBS until the
220 supernatant was clear. The resultant RBC suspension (about 200 μ L) was diluted to 9.8 mL of
PBS, producing stock RBC solution with about 2% RBC suspensions. Herein, RBCs
incubation with deionized water and PBS were used as the positive and negative controls,
respectively. 1 mL of 2% RBC suspensions were added to 1 mL samples until the final
concentration of P-ss-SA, P-SA and Tween 80 solutions ranged from 0.25 to 1 mg/mL. The
225 mixture was incubated at 37 °C for 6 h and then centrifuged at 2000 rpm for 5 min to remove
intact RBCs. The absorbance of the supernatant was measured for release of hemoglobin at
545 nm³⁵. All measurements were performed in triplicate and the percentage of hemolysis was
calculated as Hemolysis (%) = $(A_{\text{test}} - A_{\text{neg}}) / (A_{\text{pos}} - A_{\text{neg}}) \times 100\%$, where A_{test} , A_{neg} , A_{pos} are the
absorbance values of the test sample, negative control (PBS) and positive control (water),
230 respectively.

2.9. MTT assay

The cytotoxicity of blank or DOX-loaded polymeric micelles was studied by the MTT
assays using HepG2 cells and MCF-7 cells. Cells were seeded onto a 96-well plate at a density
of 1×10^4 cells per well in 100 μ L of Dulbecco's Modified Eagle medium (DMEM) containing
235 10% FBS and incubated for 24 h (37 °C, 5% CO₂). The medium was replaced by 100 μ L

samples of various concentrations of blank or DOX-loaded polymeric micelles. The cells were incubated for another 48 h, and then replaced by 100 μ L of MTT solution (0.5 mg/mL). The cells were further incubated for another 4 h, and the medium was aspirated and replaced by 100 μ L of DMSO to dissolve the resulting purple crystals. The absorbance was measured at 240 570 and 630 nm using a microplate reader (Thermo Fisher Scientific). Cell viability was expressed as a percentage of the control culture value.

2.10. CLSM observation

Confocal laser scanning microscopy (CLSM) was employed to examine the intracellular distribution of DOX. MCF-7 cells were seeded on glass bottom dishes at a density of 5×10^4 245 cells per dish in 1 mL of DMEM containing 10% FBS and incubated for 24 h (37 $^{\circ}$ C, 5% CO_2). The cells were then incubated with free DOX, DOX-loaded P-SA micelles or DOX-loaded P-ss-SA micelles at a final DOX concentration of 10 μ g/mL in DMEM for 4 h or 8 h at 37 $^{\circ}$ C. The culture media was removed and the cells were rinsed with PBS for three times to remove micelles that were not ingested by the cells. Then the nuclei were stained with 10 μ L (1 250 mg/mL) of Hoechst 33342 at 37 $^{\circ}$ C for 15 min. Finally, the cells were washed three times with PBS and incubated with 1 mL DMEM. Fluorescence images of cells were obtained with OLYMPUS FV10-ASW confocal fluorescence microscope.

2.11. Evaluation of cellular uptake by FCM

MCF-7 cells were seeded onto 6-well plates at a density of 1×10^5 cells per well in 1 mL 255 of DMEM containing 10% FBS and incubated for 24 h (37 $^{\circ}$ C, 5% CO_2). The cells were then incubated with free DOX, DOX-loaded P-SA micelles or DOX-loaded P-ss-SA micelles at a final DOX concentration of 10 μ g/mL in DMEM for 4 h and 8 h at 37 $^{\circ}$ C. The culture media

was removed and the cells were rinsed with PBS for three times to remove micelles that were not ingested by the cells. The cells were harvested by trypsinization and resuspended in PBS
260 after centrifugation (1000 rpm, 5 min) and flow cytometry was done using a BD FACSCanto™ flow cytometer (FCM).

2.12. Statistical analysis


Data were presented as mean \pm standard deviation. Statistical analysis was conducted by using one-way analysis of variance (ANOVA) and p -values < 0.05 were considered
265 statistically significant.

3. Results and discussion

3.1. Synthesis of P-ss-SA conjugates and P-SA conjugates

The synthesis schemes of P-ss-SA conjugates and P-SA conjugates were presented in Fig. 1. In order to prepare amphiphilic P-ss-SA conjugates and P-SA conjugates, P was first
270 modified with succinic anhydride to introduce carboxyl groups. For reduction-sensitive P-ss-SA conjugate, cystamine was used as linker to couple pullulan succinate (P-COOH) and SA. The non-reduction-sensitive P-SA conjugate using adipic dihydrazide to link P-COOH and SA with both amide bonds was synthesized as control. In our preliminary experiments, stearic acid modified P derivatives with different degrees of substitution were synthesized
275 based on our previous report and other research.^{40, 41} We found that conjugates with degree of substitution (DS, number of SA residues per 100 glucose units in pullulan) of around 5 might be beneficial for the formation of nanomicells which possess good physicochemical properties. Conjugates with lower DS were prone to the formation of nanomicelles with larger size and less stability. Conjugates with higher DS seemed to form nanomicelles which were too tight to

280 show reduction-sensitivity due to the difficult access of reducing agent to the core of nanomicelles. Thus, in this paper, we presented reduction-sensitive P-ss-SA conjugates with only one kind of DS and non-reduction-sensitive P-SA conjugate was then synthesized with a similar DS for comparison.



285 **Fig.1.** Synthetic scheme of P-ss-SA conjugate and P-SA conjugate.

The chemical structures of P-ss-SA and P-SA conjugates were confirmed using ^1H NMR, as shown in Fig. 2. The representative structure of pullulan (P) in D_2O was shown in Fig. 2(a). The broad chemical shifts in the wide region of 3.4-4.0 ppm were mainly associated with the inner methyldyne and methylene protons (CH-O and $\text{CH}_2\text{-O}$) on glucose units of pullulan. The chemical shift associated with the unique methyldyne proton (O-CH-O) of glucose units was at about 4.9 ppm.³⁵ For P-COOH (Fig. 2(b)), the chemical shift at the range of 2.58-2.85 ppm was associated with methylene protons ($\text{C-CH}_2\text{-CH}_2\text{-C}$) of succinic acid moieties. The degree of succinoylation quantified by titration was around 48%. For P-ADH (Fig. 2(c)), the chemical shift at the range of 2.40-2.58 ppm was associated with methylene protons ($\text{CO-CH}_2\text{-CH}_2\text{-CH}_2\text{-CH}_2\text{-CO}$) in adipic dihydrazide. For P-CYS (Fig. 2(e)), the chemical shift

290

295

at the range of 2.85-2.96 ppm was associated with methylene (NH-CH₂-CH₂-S) in cystamine.

For P-SA (Fig. 2(d)) and P-ss-SA (Fig. 2(f)), the chemical shift at the range of 1.1-1.3 ppm

was associated with the methylene and methyl protons (CO-(-CH₂)₁₆-CH₃) in stearic acid. The

degree of substitution (DS, defined as the number of stearic acid per 100 sugar residues in

300 pullulan) for the P-ss-SA and P-SA micelles were 5.36 and 4.37, respectively (Table 1).




Fig.2. ¹H NMR spectra of P (a), P-COOH (b), P-ADH (c), P-SA (d), P-CYS (e), P-ss-SA (f).

Table 1. Properties of P-SA conjugate and P-ss-SA conjugate (mean ± SD, n = 3)

sample	DS ^a	CMC ^b (mg/L)	Size ^c (nm)	PDI ^c	Zeta potential ^c (mV)
P-SA	4.37	88.23	194.8 ± 2.2	0.227 ± 0.002	-16.1 ± 2.2
P-ss-SA	5.36	51.24	187.7 ± 7.8	0.228 ± 0.013	-25.9 ± 4.2

^a Degree of substitution of stearic acid.

305 ^b Measured using pyrene as a fluorescence probe.

^c Micelle size and zeta potential was measured by DLS.

3.2. Preparation and characterization of micelles

310 The reduction-sensitive P-ss-SA and non-reduction-sensitive P-SA micelles were prepared by a simple dialysis method. The particle size of P-ss-SA and P-SA micelles measured by Dynamic light scattering (DLS) were 187.7 ± 7.8 nm and 194.8 ± 2.2 nm, respectively (Table 1). The morphology of P-ss-SA and P-SA micelles was observed by TEM, and as shown in Fig. 3, both P-ss-SA and P-SA micelles were approximate spherical in shape
315 and the mean size was 26.9 ± 8.2 nm and 29.7 ± 10.9 nm, respectively. The size measured from TEM was smaller than that from DLS. This difference probably was because the samples for TEM undergo a shrinkage due to water evaporation under air-drying, while size determination by DLS was conducted under aqueous condition.^{27, 29, 30} Additionally, because only part of the carboxyl group of P-COOH was modified with cystamine or adipic
320 dihydrazide,^{27, 29} the zeta potential of P-ss-SA and P-SA micelles were around -25.9 mV and -16.1 mV, respectively (Table 1). The negatively-charged surface provides a repelling force between the micelles and increases the stability of the micelles. No precipitation was observed in P-ss-SA or P-SA micelles solution after stewing at 4 °C for 1 month and the particle size and zeta potential didn't change much measured by DLS (Fig. 4(c)). The critical micelles
325 concentration (CMC) of amphiphilic P-ss-SA conjugates and P-SA conjugates evaluated by fluorescence spectroscopy using pyrene as a probe was 51.24 mg/L and 88.23 mg/L, respectively (Table 1). Such low CMC values suggested that the micellar structure would retain intact under highly diluted conditions after administration, which were advantageous to prolong blood circulation time.²⁷ These results suggested that the P-ss-SA micelles possess
330 suitable properties to be drug carriers.





Fig.3. TEM images of blank micelles and DOX-loaded micelles.

3.3. Disassembly of micelles triggered by DTT

To investigate reduction triggered disassemble behaviors of P-ss-SA micelles, DTT
335 which is a water-soluble reducing agents was utilized to simulate the intracellular reductive
condition. P-ss-SA micelles were treated with 10 mM DTT, a reductive environment
analogous to that of the intracellular compartments such as cytosol and the cell nucleus.⁴² At
predetermined time, the size of micelles was determined by DLS. As shown in Fig. 4(a), the
mean size of P-ss-SA micelles without DTT treatment didn't change much after 24 h, by
340 contrast, the mean size of P-ss-SA micelles increased continuously from about 188 nm to 716
nm after adding DTT for 24 h. The disulfide linkages in the side chain in the core of the
P-ss-SA micelles were reduced into free thiols after adding reducing agent DTT, which made
hydrophobic stearic acid groups detach from hydrophilic pullulan main chain and thus
resulted in the dissociation of micelles to enlarge the mean size. But the pullulan main chain
345 were very long chain, when the conjugates self-assembled into nano-micelles, the pullulan
polysaccharide backbones coiled to form hydrophilic shells, they couldn't get completely

decomposed in 24 h. Such trend was also observed in other amphiphilic copolymers.^{7, 29, 42, 43}

On the other hand, for P-SA micelles with or without DTT treatment (Fig. 4(b)), the mean micelle size didn't change much.



350

Fig.4. The size change of P-ss-SA micelles (a) and P-SA micelles (b) in response to 10mM DTT and the stability of P-ss-SA micelles (c) in PBS (10mM, pH 7.4) determined by DLS measurement.

355 3.4. Preparation and characterization of DOX-loaded micelles

DOX was chosen because it is one of the most commonly used chemotherapeutic drugs and it is easily examined for its inherent fluorescence. In this study, DOX was loaded into micelles by a simple dialysis method.^{11, 25, 30} Firstly, DOX·HCl was stirred with twice the number of moles of TEA in DMSO to detach HCl and render the drug hydrophobic. Then DOX/DMSO solution was added to P-ss-SA or P-SA in DMSO at
 360 different drug-to-carrier ratio. Then, the mixture solutions were transferred into dialysis bag (MWCO 10000) and dialyzed against deionized water for 48 h. As DMSO went out and water came in, the hydrophobic stearic

acid groups aggregated to form many hydrophobic cores and the pullulan backbones coiled to form hydrophilic shells outside these hydrophobic cores, resulting in the formation of nano-micelles with a core-shell structure. Meanwhile, DOX was entrapped into the hydrophobic cores of micelles through its hydrophobic interactions with stearic acid groups during the formation of nano-micelles.

The properties of DOX-loaded micelles were summarized in Table 2. DOX loading capacity increased from 3.51% to 7.56% with the weight ratio of DOX to P-ss-SA increasing from 1/20 to 1/5, but entrapment efficiency decreased from 72.81% to 40.88% at the same time. Moreover, with the drug feed ratio increased, the particle size increased slightly because of the increase in the inner core volume. The DOX-loaded P-SA micelles showed the same trend with DOX-loaded P-ss-SA micelles. Thus, the optimal weight ratio 1/10 based on the drug loading properties was selected for further investigation.

The morphology of DOX-loaded micelles was also observed by TEM (Fig. 3). The mean size of DOX-loaded P-ss-SA micelles (P-ss-SA/DOX) and DOX-loaded P-SA micelles (P-SA/DOX) was 29.2 ± 4.7 nm and 30.6 ± 13.6 nm, respectively. The size measured from TEM (around 30 nm) was smaller than that from DLS (around 200 nm) because of different sample preparation technologies.^{27, 29, 30}

Table 2. Properties of DOX-loaded P-SA micelles and P-ss-SA micelles (mean \pm SD, n = 3)

sample	drug/carrier	EE ^a (%)	DL ^a (%)	size ^b (nm)	PDI ^b	Zeta potential ^b (mV)
P-SA	1/5	45.36 \pm 1.60	8.31 \pm 0.27	228.8 \pm 7.8	0.106 \pm 0.005	-16.0 \pm 6.7
	1/10	73.31 \pm 2.50	6.83 \pm 0.22	214.6 \pm 2.5	0.089 \pm 0.008	-14.9 \pm 3.3
	1/20	77.58 \pm 3.78	3.73 \pm 0.18	205.6 \pm 0.6	0.175 \pm 0.004	-13.0 \pm 0.4
P-ss-SA	1/5	40.88 \pm 1.33	7.56 \pm 0.23	220.8 \pm 5.4	0.223 \pm 0.005	-26.4 \pm 5.9
	1/10	65.53 \pm 0.78	6.19 \pm 0.06	194.4 \pm 0.4	0.213 \pm 0.010	-24.2 \pm 1.9
	1/20	72.81 \pm 6.79	3.51 \pm 0.32	190.1 \pm 5.8	0.249 \pm 0.001	-23.2 \pm 1.6

^a EE and DL are short for entrapment efficiency and drug-loading, respectively.

^b Micelle size and zeta potential was measured by DLS.

3.5. In vitro drug release from micelles triggered by DTT

In order to evaluate the reduction triggered DOX release behavior, 10 mM DTT was used to mimick the

intracellular reductive condition with reduction-sensitive DOX-loaded P-ss-SA micelles and
 385 non-reduction-sensitive DOX-loaded P-SA micelles. As shown in Fig. 5(a), the release of DOX from
 reduction-sensitive P-ss-SA micelles was significantly accelerated by adding DTT to the release media ($p <$
 0.05). The P-ss-SA micelles released more than 80% DOX in the first 5 h under 10 mM DTT. However, in the
 case without DTT, less than 60% DOX in P-ss-SA micelles was released within the same period ($p <$
 0.05). By
 contrast, the release rate and level of DOX from P-SA micelles revealed negligible change after the addition of
 390 10 mM DTT (Fig. 5(b)). These results were coincident with the outcomes illustrated in Fig. 4, the mean size of
 reduction-sensitive P-ss-SA micelles increased continuously under reductive condition due to the reductive
 cleavage of the disulfide bonds, and the encapsulated DOX released much faster and more due to the
 disassembly of the micelles. Therefore, compared with reduction-insensitive P-SA micelles, reduction-sensitive
 P-ss-SA micelles showed preferable stability and reduction sensitivity and may achieve tumor site-specific
 395 DOX delivery under reducing environment. The similar results were also reported for other reduction-sensitive
 micelles.^{25, 28, 43}





Fig.5. Reduction-triggered release of DOX from P-ss-SA micelles (a) and P-SA micelles used as a reduction insensitive control (b). Error bars represent the standard deviation of three measurements (mean \pm SD, $n = 3$).

400

3.6. Hemolysis test

In order to evaluate the blood compatibility of P-SA and P-ss-SA micelles, the hemolysis test was performed. The level of hemolysis of P-SA and P-ss-SA micelles was compared with that of Tween 80, which can cause hemolysis. As shown in Fig. 6, the hemolysis induced by Tween 80 increased dramatically from $17.51 \pm 0.47\%$ to $89.34 \pm 1.45\%$ with the concentration increasing from 0.25 mg/mL to 1 mg/mL, while the hemolysis caused by P-SA or P-ss-SA micelles were all below 2% at the same concentration range, which was significantly different from Tween 80 ($p < 0.05$). It was reported that up to 5% hemolysis is permissible for biomaterials.³⁵ Thus, both P-SA and P-ss-SA micelles have shown good blood compatibility.



410 **Fig.6.** Hemolysis test results of P-SA, P-ss-SA and Tween 80 at different concentrations. Error bars represent the standard deviation of three measurements (mean \pm SD, $n = 3$, $*p < 0.05$).

3.7. In vitro cytotoxicity studies

In order to investigate the cytotoxicity of blank micelles and DOX-loaded micelles, MTT assay was conducted against HepG2 and MCF-7 cells. As shown in Fig. 7, with the concentrations of blank micelles ranged from 25 to 200 $\mu\text{g/mL}$, the cell viability of HepG2 and MCF-7 cells against P-SA or P-ss-SA micelles after 48 h were all around 90%, which indicated that the two micelles were non-toxic to HepG2 and MCF-7 cells and fairly safe to be used as drug carriers.




Fig.7. Cytotoxicity of P-ss-SA micelles and P-SA micelles in HepG2 cells (a) and MCF-7 cells (b) after 48 h.


420

Error bars represent the standard deviation of six measurements (mean \pm SD, $n = 6$).

425

430

The in vitro cytotoxicity of DOX-loaded micelles was characterized by the half maximal inhibitory concentration (IC_{50}) to HepG2 and MCF-7 cells. The results were presented in Fig. 8. The IC_{50} of DOX-loaded P-ss-SA micelles, DOX-loaded P-SA micelles and free DOX to HepG2 cells were $0.740 \pm 0.108 \mu\text{g/mL}$, $12.181 \pm 0.589 \mu\text{g/mL}$ and $1.123 \pm 0.437 \mu\text{g/mL}$. Compared with DOX-loaded P-SA micelles, DOX-loaded P-ss-SA micelles exhibited significantly higher cytotoxicity to HepG2 cells ($p < 0.05$). This finding can be explained as the much faster release of DOX from reduction-sensitive P-ss-SA micelles by cleavage of the disulfide bond in the intracellular redox potential. The IC_{50} of DOX-loaded P-ss-SA micelles, DOX-loaded P-SA micelles and free DOX to MCF-7 cells were $0.949 \pm 0.184 \mu\text{g/mL}$, $8.493 \pm 3.997 \mu\text{g/mL}$ and $1.181 \pm 0.179 \mu\text{g/mL}$. Reduction-sensitive DOX-loaded P-ss-SA micelles also exhibited significantly superior anti-tumor activity compared with DOX-loaded P-SA micelles due to fast DOX release under the intracellular reductive conditions in MCF-7 cells. However, both DOX-loaded P-ss-SA micelles and DOX-loaded P-SA micelles didn't exhibit significantly higher cytotoxicity to HepG2 cells than to MCF-7 cells, it has to be noted that extensive chemical modification of the native polysaccharide may greatly influence its affinity for the liver.^{38, 44}



435 **Fig.8.** Cytotoxicity of P-ss-SA/DOX micelles, P-SA/DOX micelles and free DOX in HepG2 cells (a) and MCF-7 cells (b) after 48 h. Error bars represent the standard deviation of six measurements (mean \pm SD, n = 6).

3.8. In vitro cellular uptake of DOX-loaded micelles

In order to investigate the cellular uptake of DOX-loaded micelles, CLSM and FCM were used to study the cellular uptake of the two DOX-loaded micelles. CLSM images were shown in Fig. 9. Both DOX-loaded micelles could be effectively internalized in MCF-7 cells after 4 h. Free DOX presented red fluorescence in both cytoplasm and nuclei, this can be explained that DOX is a small molecule and it can quickly diffuse into cells and enter nuclei by passive diffusion.^{13,24} DOX-loaded P-SA micelles presented red fluorescence only in cytoplasm, but DOX-loaded P-ss-SA micelles presented red fluorescence not only in cytoplasm but also weak red fluorescence in nuclei. With further incubation for 8 h, Cells incubated with DOX-loaded P-ss-SA micelles presented stronger DOX fluorescence in the cytoplasm and nuclei because of more DOX released from P-ss-SA micelles under reducing environment. By contrast, almost no DOX fluorescence was observed in nuclei of the cells incubated with DOX-loaded P-SA micelles, which may be caused by the lower release rate and level of DOX from DOX-loaded P-SA micelles. Because it has been reported that at the same concentration of DOX, DOX fluorescence loaded in micelles was lower compared to that of free DOX due to the self-quenching effect of DOX in confined environment.²⁵ Therefore, the images in Fig. 9 indicated the time-dependent cellular uptake pathways of the DOX-loaded micelles and rapid DOX release from reduction-sensitive P-ss-SA micelles under

440

445

450

reductive intracellular condition because of reductive cleavage of the disulfide bonds and disassembly of the micelles.

The quantitative fluorescence intensity was further measured by FCM. The results were shown in Fig. 10.

455 It was clear that the fluorescence intensity of MCF-7 cells treated with DOX-loaded P-ss-SA micelles was significant higher than that of cells treated with DOX-loaded P-SA micelles at both 4 and 8 h. Pullulan-based nanomicelles have been reported to enter cancer cells by endocytosis and then the loaded drug was subsequently released.^{11, 13} The fluorescence signals are associated with the DOX release quantity from the micelles. Therefore, the results revealed that DOX released much faster from the reduction-sensitive P-ss-SA
460 micelles inside the cells, which is well in accordance with the CLSM observation. Hence, the reduction-sensitive P-ss-SA micelles might be used as a suitable anticancer drug carrier.




Fig.9. CLSM images of MCF-7 cells treated with DOX loaded micelles for 4 h and 8 h

(DOX dosage was 10 µg/mL).

465




Fig.10. FCM results of MCF-7 cells treated with DOX loaded micelles for 4 h ((a) and (c)) and 8 h ((b) and (d)).

DOX dosage was 10 $\mu\text{g/mL}$.

4. Conclusion

470

In this study, a novel reduction-sensitive amphiphilic polymer P-ss-SA was successfully synthesized by introducing stearic acid into pullulan with a reduction-sensitive disulfide bond. The chemical structure of P-ss-SA was confirmed by ^1H NMR. The polymer can easily self-assemble into micelles in aqueous media and encapsulate DOX. The results measured by DLS showed the mean size of blank and DOX-loaded micelles was around 190 nm, and the mean size of reduction-sensitive P-ss-SA micelles increased dramatically under

475

reductive conditions. In vitro release of DOX from reduction-sensitive P-ss-SA micelles showed a

reduction-triggered drug release under reducing environment. The confocal laser microscopy and flow cytometry measurements indicated that the intracellular reductive conditions broke the disulfide bonds in P-ss-SA micelles and triggered the fast release of DOX. The in vitro IC₅₀ of the DOX-loaded P-ss-SA micelles was lower than that of DOX-loaded P-SA to both HepG2 and MCF-7 cells. The blank micelles showed negligible cytotoxicity and possessed excellent hemocompatibility. Therefore, the biocompatible reduction-sensitive P-ss-SA micelles can be used as potential carrier systems for the intracellular delivery of DOX and enhance the anticancer efficacy.

Acknowledgements

The authors are grateful to the financial support of the NSF of China (Grant No. 21376039).

References

- 1 R. Haag and F. Kratz, *Angew Chem Int Ed Engl*, 2006, **45**, 1198-1215.
- 2 M. E. Davis, Z. G. Chen and D. M. Shin, *Nat Rev Drug Discov*, 2008, **7**, 771-782.
- 3 A. Schroeder, D. A. Heller, M. M. Winslow, J. E. Dahlman, G. W. Pratt, R. Langer, T. Jacks and D. G. Anderson, *Nat Rev Cancer*, 2012, **12**, 39-50.
- 4 C. Deng, Y. Jiang, R. Cheng, F. Meng and Z. Zhong, *Nano Today*, 2012, **7**, 467-480.
- 5 S. Mura, J. Nicolas and P. Couvreur, *Nature Materials*, 2013, **12**, 991-1003.
- 6 Q. Zhang, N. R. Ko and J. K. Oh, *Chem Commun (Camb)*, 2012, **48**, 7542-7552.
- 7 W. Chen, Y. Zou, F. Meng, R. Cheng, C. Deng, J. Feijen and Z. Zhong, *Biomacromolecules*, 2014, **15**, 900-907.
- 8 Y. Zhong, W. Yang, H. Sun, R. Cheng, F. Meng, C. Deng and Z. Zhong, *Biomacromolecules*, 2013, **14**, 3723-3730.
- 9 J. Fang, H. Nakamura and H. Maeda, *Adv Drug Deliv Rev*, 2011, **63**, 136-151.

- 10 J. Cao, T. Su, L. Zhang, R. Liu, G. Wang, B. He and Z. Gu, *Int J Pharm*, 2014, **471**, 28-36.
- 11 H. Guo, Y. Liu, Y. Wang, J. Wu, X. Yang, R. Li, Y. Wang and N. Zhang, *Carbohydr Polym*, 2014, **111**,
500 908-917.
- 12 Y. Wang, H. Chen, Y. Liu, J. Wu, P. Zhou, Y. Wang, R. Li, X. Yang and N. Zhang, *Biomaterials*, 2013,
34, 7181-7190.
- 13 Y. Wang, Y. Liu, Y. Liu, Y. Wang, J. Wu, R. Li, J. Yang and N. Zhang, *Polymer Chemistry*, 2014, **5**,
423-432.
- 505 14 L. Sun, X. Zhang, J. An, C. Su, Q. Guo and C. Li, *RSC Advances*, 2014, **4**, 20208-20215.
- 15 R. Banerjee and D. Dhara, *Langmuir*, 2014, **30**, 4137-4146.
- 16 P. Yang, D. Li, S. Jin, J. Ding, J. Guo, W. Shi and C. Wang, *Biomaterials*, 2014, **35**, 2079-2088.
- 17 S. H. Medina, M. V. Chevliakov, G. Tiruchinapally, Y. Y. Durmaz, S. P. Kuruvilla and M. E. Elsayed,
Biomaterials, 2013, **34**, 4655-4666.
- 510 18 Q. Yuan, Y. Zhang, T. Chen, D. Lu, Z. Zhao, X. Zhang, Z. Li, C.-H. Yan and W. Tan, *ACS Nano*, 2012,
6, 6337-6344.
- 19 J. Wang, G. Yang, X. Guo, Z. Tang, Z. Zhong and S. Zhou, *Biomaterials*, 2014, **35**, 3080-3090.
- 20 F. Meng, W. E. Hennink and Z. Zhong, *Biomaterials*, 2009, **30**, 2180-2198.
- 21 H. Wei, R.-X. Zhuo and X.-Z. Zhang, *Progress in Polymer Science*, 2013, **38**, 503-535.
- 515 22 A. Jhaveri, P. Deshpande and V. Torchilin, *Journal of Controlled Release*, 2014, **190**, 352-370.
- 23 R. Cheng, F. Feng, F. Meng, C. Deng, J. Feijen and Z. Zhong, *J Control Release*, 2011, **152**, 2-12.
- 24 X. Zhang, K. Achazi, D. Steinhilber, F. Kratz, J. Dervedde and R. Haag, *J Control Release*, 2014, **174**,
209-216.
- 25 C. Cui, Y. N. Xue, M. Wu, Y. Zhang, P. Yu, L. Liu, R. X. Zhuo and S. W. Huang, *Biomaterials*, 2013,

- 520 34, 3858-3869.
- 26 H. Wang, L. Tang, C. Tu, Z. Song, Q. Yin, L. Yin, Z. Zhang and J. Cheng, *Biomacromolecules*, 2013, **14**, 3706-3712.
- 27 C. Yu, C. Gao, S. Lü, C. Chen, Y. Huang and M. Liu, *Chemical Engineering Journal*, 2013, **228**, 290-299.
- 525 28 J. Yang, Y. Huang, C. Gao, M. Liu and X. Zhang, *Colloids Surf B Biointerfaces*, 2014, **115**, 368-376.
- 29 J. Li, M. Huo, J. Wang, J. Zhou, J. M. Mohammad, Y. Zhang, Q. Zhu, A. Y. Waddad and Q. Zhang, *Biomaterials*, 2012, **33**, 2310-2320.
- 30 P. Sun, D. Zhou and Z. Gan, *J Control Release*, 2011, **155**, 96-103.
- 31 J. Wang, B. Dou and Y. Bao, *Mater Sci Eng C Mater Biol Appl*, 2014, **34**, 98-109.
- 530 32 V. D. Prajapati, G. K. Jani and S. M. Khanda, *Carbohydr Polym*, 2013, **95**, 540-549.
- 33 J. C. Fricain, S. Schlaubitz, C. Le Visage, I. Arnault, S. M. Derkaoui, R. Siadous, S. Catros, C. Lalande, R. Bareille, M. Renard, T. Fabre, S. Cornet, M. Durand, A. Leonard, N. Sahraoui, D. Letourneur and J. Amedee, *Biomaterials*, 2013, **34**, 2947-2959.
- 34 H. Zhang, F. Li, J. Yi, C. Gu, L. Fan, Y. Qiao, Y. Tao, C. Cheng and H. Wu, *Eur J Pharm Sci*, 2011, **42**, 517-526.
- 535 35 X. C. Yang, Y. L. Niu, N. N. Zhao, C. Mao and F. J. Xu, *Biomaterials*, 2014, **35**, 3873-3884.
- 36 M. R. Rekha and C. P. Sharma, *Acta Biomater*, 2011, **7**, 370-379.
- 37 H. Li, S. Bian, Y. Huang, J. Liang, Y. Fan and X. Zhang, *J Biomed Mater Res A*, 2013, **102**, 150-159.
- 38 M. R. Rekha and C. P. Sharma, *Biomaterials*, 2009, **30**, 6655-6664.
- 540 39 H. Li, Y. Cui, J. Liu, S. Bian, J. Liang, Y. Fan and X. Zhang, *Journal of Materials Chemistry B*, 2014, **2**, 3500-3510.

- 40 J. Wang, D. Song and Y. Bao, *Acta Chimica Sinica*, 2012, **70**, 1193-1200.
- 41 Y.-Z. Du, Q. Weng, H. Yuan and F.-Q. Hu, *ACS Nano*, 2010, **4**, 6894-6902.
- 42 Q. Guo, P. Luo, Y. Luo, F. Du, W. Lu, S. Liu, J. Huang and J. Yu, *Colloids Surf B Biointerfaces*, 2012,
545 **100**, 138-145.
- 43 L.-Y. Tang, Y.-C. Wang, Y. Li, J.-Z. Du and J. Wang, *Bioconjugate Chem*, 2009, **20**, 1095-1099.
- 44 K. Raemdonck, T. F. Martens, K. Braeckmans, J. Demeester and S. C. De Smedt, *Adv Drug Deliv Rev*,
2013, **65**, 1123-1147.